Clinical trial
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse…
NCT00421421 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00421421 |
|---|---|
| Title | Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce The Risk of Acute Urinary Retention Relapse Following Successful Trial Without Catheter. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | Dutasteride |
| Enrollment | 276 |
| Start date | Mar 1, 2007 |
| First posted | Jan 12, 2007 |
| Last update posted | Nov 27, 2007 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: